SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009 at 8:30 a.m. GMT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered...
Over six months ago, I found myself sitting in a small pub in Oxford, chatting with friends over a pint and I had a crazy idea. I don't think I would have ever expected this idea to grow into what it has become, affect as many people as it has, or to be more successful than I could ever have imagined. Heck, had you asked that night, I probably wouldn't have even thought I had the stones to go through...
Celgene (NasdaqNM: CELG) closed yesterday at $54.01. So far the stock has hit a 52-week low of $36.90 and 52-week high of $60.42. Celgene stock has been showing support around 52.91 and resistance in the 54.69 range. Technical indicators for the stock are Bullish and S&P gives CELG a very positive 5 STAR (out of 5) strong buy rating. CELG appears on the Investors Observer Momentum Plays list. For...
George Spritzer submits: H&Q Healthcare Investors ( HQH ) appears to a be a decent value now within the closed-end fund universe. It is broadly diversified, and primarily invests in biotechnology, medical devices, pharmaceuticals and medical delivery. It also invests a limited portion of the portfolio in smaller, emerging companies and some restricted securities. In their last SEC filing (as of...
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene...
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID®, VIDAZA®, THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting...
(This guest post originally appeared at the author's blog ) Morgan Stanley North America recently released their list of best ideas – a list of actionable ideas from various sectors and analysts that rank as their leading stock investment insights ( see here for Morgan’s market outlook ). The “best ideas” are Morgan’s ideas that vary substantially from consensus, have...
“Celgene Corp (CELG) is a buy, but not yet,” Jim Cramer said, “investors should wait for the right moment before rushing in.” The biotech giant was the third name that Cramer added to his portfolio of cancer-fighting drug companies after Pfizer Inc. (PFE) and Bristol-Myers Squibb Company (BMY). Cramer went up against his colleague at [...]
Cramer often views stocks in a much shorter time frame than we do thinks that this stock may be a better trade than investment. His belief is that the stock will get a nice boost from a solid showing of Revlimid at the American Society of Hematology. He would buy the week before the meeting and look to sell after a quick pop. At Ockham, we think it is far to difficult to predict these sorts of trades,...
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company....
Videos
